5′ ALK Amplification in Neuroblastoma: A Case Report

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: 5′ ALK Amplification in Neuroblastoma: A Case Report ; volume:14 ; number:1 ; year:2021 ; pages:585-591 ; extent:7
Case reports in oncology ; 14, Heft 1 (2021), 585-591 (gesamt 7)

Creator: Akhavanfard, Sara
Nohr, Erik
AlNajjar, Mohammad
Haughn, Mollie
Hashimoto, Sayaka
Deeg, Carol
Pfau, Ruthann
Brundler, Marie-Anne
Reshmi, Shalini C.

DOI: 10.1159/000512187

URN: urn:nbn:de:101:1-2021051301003056405646

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Akhavanfard, Sara
Nohr, Erik
AlNajjar, Mohammad
Haughn, Mollie
Hashimoto, Sayaka
Deeg, Carol
Pfau, Ruthann
Brundler, Marie-Anne
Reshmi, Shalini C.

Other Objects (12)

Towards optimizing combination therapy in ALK-positive neuroblastoma

Mechanistic insights into ALK inhibitor resistance in neuroblastoma

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Subfrontal Schwannoma Mimicking Neuroblastoma: Case Report

Hochschulschrift

Targeted therapy of neuroblastoma with HDAC8 inhibitor and ALK inhibitor

DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling

Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report

Towards optimizing combination therapy in ALK-positive neuroblastoma

Mechanistic insights into ALK inhibitor resistance in neuroblastoma

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Subfrontal Schwannoma Mimicking Neuroblastoma: Case Report

Hochschulschrift

Targeted therapy of neuroblastoma with HDAC8 inhibitor and ALK inhibitor

DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling

Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report

Towards optimizing combination therapy in ALK-positive neuroblastoma

Mechanistic insights into ALK inhibitor resistance in neuroblastoma

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Subfrontal Schwannoma Mimicking Neuroblastoma: Case Report

Hochschulschrift

Targeted therapy of neuroblastoma with HDAC8 inhibitor and ALK inhibitor

DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling

Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

5′ ALK Amplification in Neuroblastoma: A Case Report

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Towards optimizing combination therapy in ALK-positive neuroblastoma

Mechanistic insights into ALK inhibitor resistance in neuroblastoma

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Subfrontal Schwannoma Mimicking Neuroblastoma: Case Report

Targeted therapy of neuroblastoma with HDAC8 inhibitor and ALK inhibitor

DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling

Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report

Towards optimizing combination therapy in ALK-positive neuroblastoma

Mechanistic insights into ALK inhibitor resistance in neuroblastoma

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Subfrontal Schwannoma Mimicking Neuroblastoma: Case Report

Targeted therapy of neuroblastoma with HDAC8 inhibitor and ALK inhibitor

DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling

Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report

Towards optimizing combination therapy in ALK-positive neuroblastoma

Mechanistic insights into ALK inhibitor resistance in neuroblastoma

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Subfrontal Schwannoma Mimicking Neuroblastoma: Case Report

Targeted therapy of neuroblastoma with HDAC8 inhibitor and ALK inhibitor

DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling

Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report

Related objects

Reset password